In the News

New MSK research uncovers why some leukemia patients stop responding to promising new drugs; examines how bone’s hardness shapes the immune battle against metastasis; shows how a telehealth tobacco treatment program helps cancer patients quit smoking; creates the first atomic-level images of a key phosphate transporter that could inform treatment of ovarian cancer and kidney disease; finds Medicare Advantage patients with cancer receive optimal treatment at lower cost; and studies how much tissue surgeons should remove for tumor-related epilepsy.

New MSK research uses saturation genome editing to better understanding of the RAD51C gene, which has been linked to higher risks of breast and ovarian cancer; sheds new light on brain metastasis; and finds a commercially available contrast dye could help surgeons better separate cancer from healthy tissue.

Research points to the role of a protein called MYB, which has long been known to play a role in cancer.

Learn how MSK uses TIL therapy for melanoma — the first cell therapy approved by the FDA to treat a solid tumor.

New MSK research identifies new cancer-specific targets for T cell receptor immunotherapy approaches; sheds light on a critical process in sexual reproduction; describes how regulatory T cells help prevent intestinal inflammation; and uncovers how the spleen helps natural killer immune cells adapt to new threats.

Lab mice who had lactose removed from their diets had a decreased risk of infection with the Enterococcus bacterium.

A new treatment is approved for an especially aggressive kind of colorectal cancer.

A large study that analyzed nearly 120,000 cells in a developing mouse embryo is full of surprises.

MSK Kids is leading a major effort to fully deliver on the promise of precision medicine for our youngest patients.

A new study is challenging the perception that mesothelioma affects only older men. Learn why MSK experts say the medical community should be aware of this rare cancer's early symptoms.